XLRN News and Press, Acceleron Pharma Inc. From 09/09/19

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to s...

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2019 Q2 earnings Read more ...

Acceleron Pharma Inc. (XLRN) Q2 2019 Earnings Conference Call August 00, 2019 05:00 PM ET Company Participants Ed Joyce - Director, IR Habib Dable - CEO Kevin McLaughlin - CFO John Quisel - CBO Sujay Kango - CCO Todd James - VP, IR and Corporate Communications Conference...

Acceleron Pharma (NASDAQ: XLRN ): Q2 GAAP EPS of -$0.34 misses by $0.11 . More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- BLA and MAA filings of luspatercept for beta-thalassemia- and myelodysplastic syndromes-associated anemia accepted by U.S. Food and Drug Administration and European Medicines Agency, respectively - - Acceleron receives $25 million milestone payment from Celgene for luspaterceptȁ...

AEIS , AEL , ANSS , APLE , APU , ATSG , AVID , AWR , AXNX , BHF , BKD , BKH , BWXT , CAR , CBPO , CBT , CDEV , CLR , COHU , CSOD , CXW , CYH , CZR , DEI , DIOD , DOOR , DRH , EVBG , FRPT , FRTA , GPRE , HIIQ , HLIO , HPR , IFF , IPAR , ITRI , IVC , KLA...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, August 5, 2019 at 5:00 p.m. EDT to discuss its second quarter 2019 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/...

Quick Take Fulcrum Therapeutics ( FULC ) has filed to raise gross proceeds of $76.5 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing treatments for genetically-defined diseases with high unmet medical need and an initial focus on rare diseases...

- Company now expects to report top-line results in the first quarter of 2020 - Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today it has co...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that company co-founder Tom Maniatis, PhD, is retiring from his position on its Board of Director...